News

May 4, 2024

Lyvgen Biopharma, a leader in developing innovative co-stimulation agonistic antibodies for cancer treatment, today announced two clinical studies on its 4-1BB agonistic antibody LVGN6051, also known as exlinkibart, have been selected for poster presentation at the upcoming American Society of Clinical Oncology (ASCO) annual meeting, to be held May 31 – June 4, 2024, in Chicago, IL.

Presentation Details:

Abstract Title: Efficacy, Safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in aPhase Ib dose expansion in resistant NSCLC, Melanoma, and GI malignancy. 

Author: Adil Daud, Vamsidhar Velcheti, Katherine M. Bever, Warren Allen Chow, Costantine Albany, RalphJ. Hauke, Katy K. Tsai, Michael Jon Chisamore, Jieyi Wang, C. Hubert Chan, Siqing Fu;University of California-San Francisco, San Francisco, CA; New York University, Laura and IsaacPerlmutter Cancer Center, New York, NY; Johns Hopkins University, Baltimore, MD; UCI Health,Orange, CA; Horizon Oncology & Research Center, Lafayette, IN; Nebraska Cancer Specialists,Omaha, NE; Helen Diller Family Comprehensive Cancer Center, University of California SanFrancisco, San Francisco, CA; Merck & Co., Inc., Rahway, NJ; Lyvgen Biopharma, Shanghai,China; Department of Investigational Cancer Therapeutics, The University of Texas MD AndersonCancer Center, Houston, TX

Session: Poster Session – Developmental Therapeutics—Immunotherapy

Abstract Number: 2575

Poster Bd Number: 54

Abstract Title: An open label, phase 1b/2 trial of LVGN6051 (4-1BB agonisticantibody) combined with anlotinib for refractory soft tissuesarcoma (STS). 

Author: Yan Zhou, Xianan Li, Linqing Li, Peng Zhang, Zhaoming Ye, Binghao Li, Yong Chen, Jian Zhang, Xiaomin Ding, Qunzi Zhang, Qiyuan Tan, Chunhao Zhang, Zhichang Zhang, Ting Yuan, Weiping Ji, Qingcheng Yang, Yang Dong, Jieyi Wang, C. Hubert Chan, Haiyan Hu; Shanghai Sixth People's Hospital, Shanghai, China; Hunan Cancer Hospital, Changsha, China; Henan Cancer Hospital, The Affi liated Cancer Hospital of Zhengzhou University, Zhengzhou, China; Department of Orthopedics, the Second Affi liated Hospital of Zhejiang University School of Medicine, Hangzhou, China; Department of Oncology, Shanghai Medical College, Fudan University; Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China; Department of Medical oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Orthopedics, Shanghai Jiao Tong University Affi liated Sixth People's Hospital, Shanghai, China; Lyvgen Biopharma, Shanghai, China; Shanghai Jiao Tong University Affi liated Sixth People’s Hospital, Shanghai, China 

Session: Poster Session – Sarcoma – Soft Tissue Tumors

Abstract Number: 11554

Poster Bd Number: 480

Complete abstracts will be released Thursday, May 23, 2024, at 5:00 p.m. ET. Data presented at the conference will be available to be requested via Lyvgen website (https://www.lyvgen.com/contact-us-1)
 

About Exlinkibart (LVGN6051)

Exlinkibart (LVGN6051) is a xLinkAb conditional 4-1BB agonistic monoclonal antibody with selective Fcγ-receptor IIB binding for targeted immune activation in the tumor microenvironment. The biology of xLinkAb technology and preclinical validation are described in Nature Communications 2019 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526162/) and Frontiers in Pharmacology 2022 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523430/). LVGN6051 has achieved RP2D of 4 mg/kg Q3W, showing desirable PK and PD properties, acceptable safety profile and durable objective responses in heavily pre-treated patients with various solid tumors. Registrational clinical trials of exlinkibart in melanoma, sarcoma and head and neck cancers are planned. For more information about Exlinkibart (LVGN6051) trials, visit www.clinicaltrials.gov with the identifiers NCT04130542, NCT05301764, NCT06378177 and NCT05075993.

About Lyvgen Biopharma

Lyvgen is a clinical stage innovative biotech company focused on developing novel biotherapeutics and therapies for cancer. Its proprietary xLinkAb technology platform enables discovery and development of monoclonal as well as multi-specific antibodies (next generation TCE) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate antibodies. Lyvgen has 3 leading drug candidates in phase 2 clinical development in the US and China, with clinical collaboration with big pharmaceutical companies globally. Lyvgen is positioned to develop global markets with its leading clinical assets for broad oncology indications. For more information, visit www.lyvgen.com